Physician profile
Eugene Cherny
NPI 1376679357
$3,508.34
in general payments reported to CMS, 2019-2025
21 companies · $79.07 in 2025
The $79.07 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,584 · 2020: $304 · 2021: $609 · 2022: $400 · 2023: $98.74 · 2024: $434 · 2025: $79.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $232.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,103.04 | 2019-2022 | |
| Abbvie INC. | $495.45 | 2023-2025 | Natrelle Saline-Filled Breast Implants, Botox |
| Smith+Nephew, INC. | $326.03 | 2019-2021 | |
| Mentor Worldwide LLC | $243.89 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.24 | 2019 | |
| Sanara Medtech INC. | $185.57 | 2022 | |
| Sientra, INC. | $150.10 | 2019-2022 | |
| Osiris Therapeutics INC. | $143.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $103.10 | 2019 | |
| Organogenesis INC. | $96.99 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.22 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $81.18 | 2021 | |
| Ethicon US, LLC | $62.46 | 2021 | |
| Novo Nordisk INC | $52.40 | 2019-2020 | |
| Motiva USA, LLC | $42.12 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $37.73 | 2021-2022 | |
| Avita Medical Americas, LLC | $35.08 | 2023 | Recell |
| Imbed Biosciences INC. | $27.78 | 2022 | |
| Convatec INC. | $20.12 | 2025 | |
| Nalpropion Pharmaceuticals LLC | $14.11 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Cherny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.